These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38619278)

  • 1. Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.
    Qin G; Dai J; Chien S; Martins TJ; Loera B; Nguyen QH; Oakes ML; Tercan B; Aguilar B; Hagen L; McCune J; Gelinas R; Monnat RJ; Shmulevich I; Becker PS
    Clin Cancer Res; 2024 Jun; 30(12):2659-2671. PubMed ID: 38619278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
    McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
    Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
    Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
    Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
    Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
    Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
    Awada H; Durmaz A; Gurnari C; Kishtagari A; Meggendorfer M; Kerr CM; Kuzmanovic T; Durrani J; Shreve J; Nagata Y; Radivoyevitch T; Advani AS; Ravandi F; Carraway HE; Nazha A; Haferlach C; Saunthararajah Y; Scott J; Visconte V; Kantarjian H; Kadia T; Sekeres MA; Haferlach T; Maciejewski JP
    Blood; 2021 Nov; 138(19):1885-1895. PubMed ID: 34075412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
    Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
    Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
    Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
    Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-cell survey of cellular hierarchy in acute myeloid leukemia.
    Wu J; Xiao Y; Sun J; Sun H; Chen H; Zhu Y; Fu H; Yu C; E W; Lai S; Ma L; Li J; Fei L; Jiang M; Wang J; Ye F; Wang R; Zhou Z; Zhang G; Zhang T; Ding Q; Wang Z; Hao S; Liu L; Zheng W; He J; Huang W; Wang Y; Xie J; Li T; Cheng T; Han X; Huang H; Guo G
    J Hematol Oncol; 2020 Sep; 13(1):128. PubMed ID: 32977829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
    Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
    Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
    Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
    Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
    Honda A; Koya J; Yoshimi A; Miyauchi M; Taoka K; Kataoka K; Arai S; Kurokawa M
    Exp Hematol; 2021 Sep; 101-102():42-48.e11. PubMed ID: 34333045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
    Smith CC; Viny AD; Massi E; Kandoth C; Socci ND; Rapaport F; Najm M; Medina-Martinez JS; Papaemmanuil E; Tarver TC; Hsu HH; Le MH; West B; Bollag G; Taylor BS; Levine RL; Shah NP
    Clin Cancer Res; 2021 Jul; 27(14):4003-4011. PubMed ID: 34103301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia.
    Zhou W; Xu S; Chen X; Wang C
    Hematology; 2021 Dec; 26(1):170-178. PubMed ID: 33538241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.